Show simple item record

dc.contributor.authorRodríguez-Izquierdo, Ignacio
dc.contributor.authorSepulveda-Crespo, Daniel 
dc.contributor.authorLasso, Jose María
dc.contributor.authorResino, Salvador 
dc.contributor.authorMuñoz-Fernández, María Ángeles
dc.date.accessioned2022-05-26T11:46:43Z
dc.date.available2022-05-26T11:46:43Z
dc.date.issued2022-05
dc.identifier.citationWiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1774.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14552
dc.description.abstractAlthough a wide variety of topical microbicides provide promising in vitro and in vivo efficacy, most of them failed to prevent sexual transmission of human immunodeficiency virus type 1 (HIV-1) in human clinical trials. In vitro, ex vivo, and in vivo models must be optimized, considering the knowledge acquired from unsuccessful and successful clinical trials to improve the current gaps and the preclinical development protocols. To date, dendrimers are the only nanotool that has advanced to human clinical trials as topical microbicides to prevent HIV-1 transmission. This fact demonstrates the importance and the potential of these molecules as microbicides. Polyanionic dendrimers are highly branched nanocompounds with potent activity against HIV-1 that disturb HIV-1 entry. Herein, the most significant advancements in topical microbicide development, trying to mimic the real-life conditions as closely as possible, are discussed. This review also provides the preclinical assays that anionic dendrimers have passed as microbicides because they can improve current antiviral treatments' efficacy.es_ES
dc.description.sponsorshipThis work has been (partially) funded by the RD16/0025/0019 projects as part of Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (2013–2016) and cofinanced by Instituto de Salud Carlos III (ISCIII) and Fondo Europeo de Desarrollo Regional (FEDER), RETIC PT17/0015/0042, Fondo de Investigacion Sanitaria (FIS) (grant no. PI16/01863) and EPIICAL project. COST CA17140 Cancer Nanomedicine-“From the Bench to Bedside.” This work has also been supported by the Ministry of Economy and Competitiveness #CGL2013-40564-R and Gordon and Betty Moore Foundation grant no. 5334. This work was also funded by research grants from ISCIII (grant numbers PI20CIII/00004, and RD16CIII/0002/0002) to Salvador Resino. The study was also funded by the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CB21/13/00044). DS-C is a “Sara Borrell” researcher from ISCIII (grant no. CD20CIII/00001).es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHIV-1es_ES
dc.subjectAcceptabilityes_ES
dc.subjectDendrimeres_ES
dc.subjectPreclinical stepses_ES
dc.subjectRegulationes_ES
dc.subjectVaginal microbicidees_ES
dc.titleBaseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicideses_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID35018739es_ES
dc.format.volume14es_ES
dc.format.number3es_ES
dc.format.pagee1774es_ES
dc.identifier.doi10.1002/wnan.1774es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderPlan Nacional de I+D+i (España)es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderGordon and Betty Moore Foundationes_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)es_ES
dc.contributor.funderUnión Europea. European Cooperation in Science and Technology (COST)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1939-0041es_ES
dc.relation.publisherversionhttps://doi.org/10.1002/wnan.1774es_ES
dc.identifier.journalWiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/CA17140es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0019/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//CGL2013-40564-R/ES/GENOMICA DE VIRUS INDIVIDUALES. UNA NUEVA VISION PARA EXPLORAR LA VIRIOSFERA NO CULTIVADA: DEL ECOSISTEMA AL HOMBRE/ es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/null/PLATAFORMAS DE APOYO A LA INVESTIGACION EN CIENCIAS Y TECNOLOGIAS DE LA SALUD (2017)/PT17/0015/0042es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00004es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CB21/13/00044es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/CD20CIII/00001es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI16/01863es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional